研究実績

Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

Hisato Kawakami, Kazuhiro Nishikawa, Toshio Shimokawa, Kazumasa Fujitani, Shigeyuki Tamura, Shunji Endo, Michiya Kobayashi, Junji Kawada, Yukinori Kurokawa, Akira Tsuburaya, Takaki Yoshikawa, Junichi Sakamoto, Taroh Satoh, for HERBIS-2, -4 and XParTS II study investigators.  The Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) and the Epidemiological and Clinical Research Information Network (ECRIN)           ESMO-GI 2022, Barcelona, Spain, 29 Jun- 2 Jul 2022

前の記事 次の記事 一覧ページへ戻る